Fate Therapeutics (FATE) Total Non-Current Liabilities (2012 - 2026)

Fate Therapeutics (FATE) has 15 years of Total Non-Current Liabilities data on file, last reported at $284.6 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 28.58% year-over-year to $284.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $284.6 million (down 28.58% YoY) and the FY2025 annual result came in at $318.7 million, down 27.61% from the prior year.
• Total Non-Current Liabilities retreated to $284.6 million in Q1 2026, from $318.7 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $842.6 million in Q1 2022 to a low of $284.6 million in Q1 2026.
• A 5-year average of $534.5 million and a median of $527.6 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities decreased 9.08% — and 2025, when it plunged 30.48%.
• Tracing FATE's Total Non-Current Liabilities over 5 years: stood at $701.7 million in 2022, then retreated by 28.05% to $504.9 million in 2023, then decreased by 12.82% to $440.2 million in 2024, then fell by 27.61% to $318.7 million in 2025, then retreated by 10.7% to $284.6 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $284.6 million (Q1 2026), $318.7 million (Q4 2025), and $343.3 million (Q3 2025), per Business Quant data.